Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
SurModics (SRDX) PT Lowered to $63 at Needham & Company
November 1, 2019 7:30 AM EDTNeedham & Company analyst Mike Matson lowered the price target on SurModics (NASDAQ: SRDX) to $63.00 (from $68.00) while maintaining a Buy rating.
The analyst commented, "Full data from GALACTIC-HF remains on track for 2021. We continue to view omecamtiv as the backbone to our CYTK... More
SurModics (SRDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
October 31, 2019 4:17 PM EDTSurModics (NASDAQ: SRDX) reported Q4 EPS of $0.37, in-line with the analyst estimate of $0.37. Revenue for the quarter came in at $30.8 million versus the consensus estimate of $28.36 million.
Summary of Fourth Quarter and Recent Highlights
Revenue of $30.8 million, an increase of 33.8% year-over-yearGAAP EPS of $0.26, non-GAAP EPS of $0.37Completed enrollment in TRANSCEND pivotal clinical trial for... More